Incannex Healthcare Revenue

Incannex Healthcare had revenue of $98.00K in the twelve months ending March 31, 2025. In the fiscal year ending June 30, 2024, Incannex Healthcare had annual revenue of $12.00K.

Revenue (ttm)

$98.00K

Revenue Growth

n/a

P/S Ratio

38.28

Revenue / Employee

$10,889

Employees

Market Cap

19.60M

Revenue Chart

Revenue History

Fiscal Year End	Revenue	Change	Growth
Jun 30, 2024	12.00K	-	-
Jun 30, 2023	-	-	-
Jun 30, 2022	539.05K	-883.65K	-62.11%
Jun 30, 2021	1.42M	1.01M	240.67%
Jun 30, 2020	417.62K	416.53K	38,249.13%
Jun 30, 2019	Pro	Pro	Pro
Jun 30, 2018	Pro	Pro	Pro
Jun 30, 2017	Pro	Pro	Pro
Jun 30, 2016	Pro	Pro	Pro

Sources: Historical revenue is based on company filings submitted to the U.S. Securities and Exchange Commission (SEC). The most recent revenue numbers may be taken from company press releases.

Revenue Definition

Revenue, also called sales, is the amount of money a company receives from its business activities, such as sales of products or services. Revenue does not take any expenses into account and is therefore different from profits.

Full Definition

Related Stocks

Company Name	Revenue
UnitedHealth Group	410.06B
Johnson & Johnson	89.33B
Merck & Co.	63.92B
AbbVie	57.37B
AstraZeneca	54.98B
Novartis AG	53.22B
Eli Lilly and Company	49.00B
Novo Nordisk	43.92B

Revenue Rankings

IXHL News

3 days ago - Incannex Healthcare Expands Clinical Advisory Board to Support Obstructive Sleep Apnea Program with Appointment of Dr. Douglas B. Kirsch - GlobeNewsWire
9 days ago - Incannex achieves key milestone with database lock for RePOSA Phase 2 trial of IHL-42X - GlobeNewsWire
10 days ago - Incannex Healthcare Forms Joint Venture with Mind Medicine Australia to Expand Access to Psychedelic-Assisted Therapy - GlobeNewsWire
15 days ago - Incannex Healthcare Cancels All Outstanding Series A Warrants Following Strategic ATM Execution - GlobeNewsWire
24 days ago - Incannex Healthcare Inc. Expands IHL-42X Clinical Advisory Board with Appointments of Four Industry and Academic Leaders to Advance Obstructive Sleep Apnea (OSA) Program - GlobeNewsWire
4 weeks ago - Incannex Healthcare Inc. Advances IHL-42X RePOSA Trial to Phase 3 Following FDA Protocol Clearance - GlobeNewsWire
4 weeks ago - Stonegate Updates Coverage on Incannex Healthcare Inc. (IXHL) 3Q 2025 - Newsfile Corp
4 weeks ago - Incannex Healthcare Inc. Enters Agreement to Cancel Remaining Series A Warrants, Eliminating Up to 347.2 Million Shares from Potential Dilution Ahead of IHL-42X Phase 2 Topline Results - GlobeNewsWire

More News